Klein, David J <br/><br/>
Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.  [electronic resource] 

 -  Diabetes technology & therapeutics  Oct 2014 
 - 679-87 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-8593 
<br/><br/><label>Standard No.: </label>10.1089/dia.2013.0366  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Age of Onset<br/>Belgium--epidemiology<br/>Blood Glucose--drug effects<br/>Body Weight--drug effects<br/>Child<br/>Diabetes Mellitus, Type 2--blood<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Glucagon-Like Peptide 1--administration & dosage<br/>Glycated Hemoglobin--drug effects<br/>Humans<br/>Hypoglycemic Agents--administration & dosage<br/>Liraglutide<br/>Pediatric Obesity--complications<br/>Prevalence<br/>Slovenia--epidemiology<br/>Treatment Outcome<br/>United Kingdom--epidemiology<br/>United States--epidemiology<br/>Weight Loss--drug effects